Healthcare / Medical DevicesKOSDAQ
$8120.00
-140.00 (-1.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.1B · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$304.6B
P/E
33.0x
↑EV/EBITDA
23.6x
↑ROE
19.7%
↑Gross Margin
79.2%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+34.4%
FCF CAGR
+9.8%
FCF margin
9.2%
FCF / Net income
0.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $37.94B · net income $9.21B · FCF $3.49B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $37.94B | $37.94B | $28.83B | $17.50B | $15.62B |
| Net Income | $9.21B | $9.21B | $5.35B | $871.8M | $1.21B |
| EBITDA | $12.65B | $12.65B | $8.42B | $2.97B | $3.06B |
| EPS | 246.00 | 246.00 | 173.00 | 29.00 | 40.00 |
| Gross Margin | 79.2% | 79.2% | 72.5% | 74.1% | 67.3% |
| Operating Margin | 27.4% | 27.4% | 23.1% | 8.9% | 11.4% |
| Net Margin | 24.3% | 24.3% | 18.6% | 5.0% | 7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.10 | 0.92 | 1.05 |
| Current Ratio | 5.51 | 5.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.49B | $3.49B | $3.13B | $-115.8M | $2.63B |
| Returns | |||||
| ROE | 19.7% | 19.7% | 27.3% | 13.0% | 22.2% |
| Valuation | |||||
| P/E | 33.01 | 33.01 | — | — | — |
| EV/EBITDA | 23.63 | 23.63 | — | — | — |
| P/B | 6.50 | 6.50 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 31.6% | 31.6% | 64.8% | 12.0% | — |
| EPS Growth | 42.2% | 42.2% | 496.6% | -27.5% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
43.1%
EPS terminal req.
$720.51
Spread vs growth
-0.9%
5Y implied EPS CAGR
28.8%
EPS terminal req.
$871.82
Spread vs growth
13.4%
10Y implied EPS CAGR
19.0%
EPS terminal req.
$1404.08
Spread vs growth
23.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.1%
Start / end P/E
67.5x → 33.0x
EPS bridge
173.00 → 246.00
Residual
-21.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.